News
Cardior announces first patient dosed in phase 2 trial
Cardior has announced the dosing of the first patient in their multicentre phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction (MI).